Q2 2022 Invex Therapeutics Ltd Activities Report Call Transcript
Thank you for standing by, and welcome to the Invex Therapeutics quarterly investor conference call. All participants are in a listen-only mode. There will be a presentation followed by a question-and-answer session. (Operator Instructions) I would now like to hand the conference over to Dr. Tom Duthy, Executive Director. Please go ahead.
Thank you, Melanie. Good afternoon, everyone. It's my pleasure to present to you a summary of the company's quarterly activities and financial performance for the three months ended December 31, 2021. I trust all of you on today's call have had a chance to read the updated announcement as lodged with ASX this morning. I will now provide an overview of the company's quarterly performance and 2022 outlook.
From a financial perspective, Invex continues to maintain a strong balance sheet with cash outflows from operating activities of $0.6 million for the quarter and closing cash and cash equivalents of $31.4 million. The quarter included a two -- a $0.2 million
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |